Filing Flows › Health Care › Integra Lifesciences Holdings (IART)
Integra Lifesciences Holdings (IART) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 23, 2026 · Integra Lifesciences Holdings (IART) Q3 2026 earnings results →
Q3 2026 Revenue up 2% year over year to $411M · 4¢ of every $1 of revenue kept as net profit · operating margin 4.6%
Integra Lifesciences Holdings made $411M in Q3 2026 (+2% Y/Y): Specialty Surgery $304M, Tissue Reconstruction $107M. Operating margin 4.6%, net earnings $14.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 23, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $411.2M in Q3 2026, up 2% year over year and down 2% from the previous quarter. Specialty Surgery was the largest line at 74% of revenue. Specialty Surgery added $11.5M year over year (up 4%), 127% of the total change. Tissue Reconstruction declined 2%.
Operating profit was $18.9M, a 4.6% margin (up 1.7 points year over year). Of the extra revenue versus Q3 2025, 78% reached operating profit, above the 3% margin then. Total costs grew 1% against revenue growth of 2%. Net earnings were $14.9M. The effective tax rate was 5.2%.
Operating cash flow was $96.0M (up 135% year over year), 646% of net earnings. Non-cash charges added back $2.9M of share-based compensation. Working capital and other items added $78.2M. After purchases of property and equipment ($10.2M), free cash flow as the company reports it was $85.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 23, 2026 | $411M | +2% | 4.6% | $14.9M | $96.0M |
| Q2 2026 | 10-Q | Jul 29, 2026 | $419M | +0.8% | 4.6% | $4.5M | $22.8M |
| Q1 2026 | 10-Q | May 5, 2026 | $392M | +2% | 2.9% | −$4.6M | $9.8M |
| Q4 2025 | 10-K | Feb 26, 2026 | $435M | -2% | 5.3% | −$1.7M | $11.8M |
| Q3 2025 | 10-Q | Oct 30, 2025 | $402M | +6% | 2.9% | −$5.4M | $40.9M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $416M | -0.6% | -123.4% | −$484M | $8.9M |
| Q1 2025 | 10-Q | May 5, 2025 | $383M | +4% | -4.0% | −$25.3M | −$11.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Integra Lifesciences Holdings
Integra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”). The CSS segment, which represents approximately 70% of our total revenue, consists of market-leading technologies and instrumentation used for a wide range of specialties, such as neurosurgery, neurocritical care, and otolaryngology, commonly referred to as ear, nose, and throat (“ENT”). We are the world leader in neurosurgery and one of the top three providers in the U.S.
In its own words, from its 10-K, filed Feb 26, 2026.
Integra Lifesciences Holdings against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +2% against the peers' median +5%. Operating margin: 4.6% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IART Integra Lifesciences Holdings | Q3 2026 | $411M | +2% | 4.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Integra Lifesciences Holdings 10-Q on SEC EDGAR · CIK 917520 · Surgical & Medical Instruments & Apparatus
13F: who owns IART and who is buying
More on IART
- How Integra Lifesciences Holdings makes money: revenue by segment
- Integra Lifesciences Holdings stock forecast, price target and fair value
- Who owns Integra Lifesciences Holdings stock: holders, funds and Congress trades
- Integra Lifesciences Holdings guidance and outlook
- Integra Lifesciences Holdings recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Integra Lifesciences Holdings guidance history: guided vs reported
- Integra Lifesciences Holdings free cash flow by quarter
- Integra Lifesciences Holdings R&D spending by quarter
- Integra Lifesciences Holdings capital expenditures by quarter
- Integra Lifesciences Holdings Specialty Surgery revenue by quarter
- Integra Lifesciences Holdings Tissue Reconstruction revenue by quarter